| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
|
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
|
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
| Lowering the boom on lower-risk myelodysplastic syndromes |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
|
Blood Advances |
Aplastic Anemia |
| Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls? |
|
Haematologica |
Aplastic Anemia |
| Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
